B7-H3 increases thymidylate synthase expression via the PI3k-Akt pathway

Tumor Biology

Volumn 37, Issue 7, 2016, Pages 9465-9472

  Jiang, Bo ^a   Liu, Fen ^a   Liu, Zhi Hui ^a   Zhang, Ting ^a   Hua, Dong ^a  

^a JIANGNAN UNIVERSITY   (China)

Author keywords

5 FU resistance; B7 molecules; B7 H3; Colon cancer; PI3K Akt; Thymidylate synthase

Indexed keywords

B7 H3 PROTEIN; CELL PROTEIN; FLUOROURACIL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN KINASE B; THYMIDYLATE SYNTHASE; UNCLASSIFIED DRUG; ANTINEOPLASTIC ANTIMETABOLITE; B7 ANTIGEN; CD276 PROTEIN, HUMAN; MESSENGER RNA; TUMOR MARKER;

ARTICLE; CANCER RESISTANCE; CELL ASSAY; COLORECTAL CANCER CELL LINE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INDUCTION; HCT8 CELL; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; SIGNAL TRANSDUCTION; SW80 CELL; APOPTOSIS; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG RESISTANCE; FLUORESCENT ANTIBODY TECHNIQUE; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR CELL CULTURE; WESTERN BLOTTING;

ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; B7 ANTIGENS; BIOMARKERS, TUMOR; BLOTTING, WESTERN; CELL PROLIFERATION; COLORECTAL NEOPLASMS; DRUG RESISTANCE, NEOPLASM; FLUORESCENT ANTIBODY TECHNIQUE; FLUOROURACIL; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PHOSPHATIDYLINOSITOL 3-KINASES; PROTO-ONCOGENE PROTEINS C-AKT; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SIGNAL TRANSDUCTION; THYMIDYLATE SYNTHASE; TUMOR CELLS, CULTURED;

EID: 84954550166     PISSN: 10104283     EISSN: 14230380     Source Type: Journal    
DOI: 10.1007/s13277-015-4740-0     Document Type: Article

References (55)

1. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384:1109–17.
2. Ribas AWJD, Robert C. Updated clinical efficacy of the anti-pd-1 monoclonal antibody pembrolizumab (pembro, mk-3475) in 411 patients (pts) with melanoma (mel). Pigment Cell Melanoma Res. 2014;27:1222.
3. D’Angelo S.P. LJ, Weber J: Smr; 2014. Efficacy and safety of nivolumab vs investigator’s choice chemotherapy (icc) in subgroups of patients with advanced melanoma after prior anti-ctla-4 therapy. (Abstract LBA)
4. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, et al. Nivolumab in previously untreated melanoma without braf mutation. N Engl J Med. 2015;372:320–30.
5. Tsai KK, Daud AI. The role of anti-pd-1/pd-l1 agents in melanoma: progress to date. Drugs. 2015;75:563–75.
6. Ramalingam S.S. MJ, Planchard D. Presented at: 2014 multidisciplinary symposium in thoracic oncology; October 30–November 1; Chicago, IL. 2014. Phase ii study of nivolumab (anti-pd-1, bms-936558, ono-4538) in patients with advanced, refractory squamous non-small cell lung cancer. (Abstract Number: LB2)
7. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, et al. Mpdl3280a (anti-pd-l1) treatment leads to clinical activity in metastatic bladder cancer. Nature. 2014;515:558–62.
8. Nanda R. CLQ, Dees E.C., Berger R., Gupta S., Geva R. S.: Antonio breast cancer symposium, December 9–13, 2014. KEYNOTE 2014;012: triple negative breast cancer.
9. Ascierto PA, Marincola FM. The year of anti-pd-1/pd-l1s against melanoma and beyond. EBioMedicine. 2015;2:92–3.
10. Sun M, Richards S, Prasad DV, Mai XM, Rudensky A, Dong C. Characterization of mouse and human b7-h3 genes. J Immunol. 2002;168:6294–7.
11. Hu Y, Lv X, Wu Y, Xu J, Wang L, Chen W, et al. Expression of costimulatory molecule b7-h3 and its prognostic implications in human acute leukemia. Hematology. 2015;20:187–95.
12. Baral A, Ye HX, Jiang PC, Yao Y, Mao Y. B7-h3 and b7-h1 expression in cerebral spinal fluid and tumor tissue correlates with the malignancy grade of glioma patients. Oncology letters. 2014;8:1195–201.
13. Wang F, Wang G, Liu T, Yu G, Zhang G, Luan X. B7-h3 was highly expressed in human primary hepatocellular carcinoma and promoted tumor progression. Cancer Investig. 2014;32:262–71.
14. Sun J, Mao Y, Zhang YQ, Guo YD, Mu CY, Fu FQ, et al. Clinical significance of the induction of macrophage differentiation by the costimulatory molecule b7-h3 in human non-small cell lung cancer. Oncology letters. 2013;6:1253–60.
15. Maeda N, Yoshimura K, Yamamoto S, Kuramasu A, Inoue M, Suzuki N, et al. Expression of b7-h3, a potential factor of tumor immune evasion in combination with the number of regulatory t cells, affects against recurrence-free survival in breast cancer patients. Ann Surg Oncol. 2014;21 Suppl 4:S546–54.
16. Chavin G, Sheinin Y, Crispen PL, Boorjian SA, Roth TJ, Rangel L, et al. Expression of immunosuppresive b7-h3 ligand by hormone-treated prostate cancer tumors and metastases. Clin Cancer Res. 2009;15:2174–80.
17. Roth TJ, Sheinin Y, Lohse CM, Kuntz SM, Frigola X, Inman BA, et al. B7-h3 ligand expression by prostate cancer: A novel marker of prognosis and potential target for therapy. Cancer Res. 2007;67:7893–900.
18. Wang J, Chong KK, Nakamura Y, Nguyen L, Huang SK, Kuo C, et al. B7-h3 associated with tumor progression and epigenetic regulatory activity in cutaneous melanoma. J Invest Dermatol. 2013;133:2050–8.
19. Zhao X, Li DC, Zhu XG, Gan WJ, Li Z, Xiong F, et al. B7-h3 overexpression in pancreatic cancer promotes tumor progression. Int J Mol Med. 2013;31:283–91.
20. Siegel R, Desantis C, Jemal A. Colorectal cancer statistics, 2014. CA Cancer J Clin. 2014;64:104–17.
21. Ingebrigtsen VA, Boye K, Nesland JM, Nesbakken A, Flatmark K, Fodstad O. B7-h3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcome. BMC Cancer. 2014;14:602.
22. Bin Z, Guangbo Z, Yan G, Huan Z, Desheng L, Xueguang Z. Overexpression of b7-h3 in cd133+ colorectal cancer cells is associated with cancer progression and survival in human patients. J Surg Res. 2014;188:396–403.
23. Ingebrigtsen VA, Boye K, Tekle C, Nesland JM, Flatmark K, Fodstad O. B7-h3 expression in colorectal cancer: nuclear localization strongly predicts poor outcome in colon cancer. Int J Cancer Journal international du cancer. 2012;131:2528–36.
24. Zhang T, Jiang B, Zou ST, Liu F, Hua D. Overexpression of b7-h3 augments anti-apoptosis of colorectal cancer cells by jak2-stat3. World J Gastroenterol. 2015;21:1804–13.
25. Liu F, Zhang T, Zou S, Jiang B, Hua D. B7h3 promotes cell migration and invasion through the jak2/stat3/mmp9 signaling pathway in colorectal cancer. Mol Med Rep. 2015.
26. Zang X, Allison JP. The b7 family and cancer therapy: costimulation and coinhibition. Clin Cancer Res. 2007;13:5271–9.
27. Fukushima M, Morita M, Ikeda K, Nagayama S. Population study of expression of thymidylate synthase and dihydropyrimidine dehydrogenase in patients with solid tumors. Int J Mol Med. 2003;12:839–44.
28. Diasio RB, Johnson MR. The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil. Pharmacology. 2000;61:199–203.
29. Silvestris N, Marech I, Brunetti AE, Azzariti A, Numico G, Cicero G, et al. Predictive factors to targeted treatment in gastrointestinal carcinomas. Cancer Biomark. 2014;14:151–62.
30. Wang L, Wang R, Pan Y, Sun Y, Zhang J, Chen H. The pemetrexed-containing treatments in the non-small cell lung cancer is -/low thymidylate synthase expression better than +/high thymidylate synthase expression: a meta-analysis. BMC Cancer. 2014;14:205.
31. Arima S, Tachikawa D, Kawahara K, Futami K. Thymidylate synthase activity after preoperative administration of 5-fu in patients with gastric or colorectal cancer. Gan to kagaku ryoho Cancer & chemotherapy. 2000;27:703–10.
32. Ishida H, Shirakawa K, Ohsawa T, Sobajima J, Hayashi Y, Nakada H, et al. Expression of mrna levels of thymidylate synthase, dihydropyrimidine dehydrogenase, and orotate phosphoribosyltransferase of colorectal cancer--relationships among mrna levels in association with response to 5-fu based treatment. Gan to kagaku ryoho Cancer & chemotherapy. 2005;32:1929–34.
33. Kamoshida S, Matsuoka H, Ishikawa T, Maeda K, Shimomura R, Inada K, et al. Immunohistochemical evaluation of thymidylate synthase (ts) and p16ink4a in advanced colorectal cancer: implication of ts expression in 5-fu-based adjuvant chemotherapy. Jpn J Clin Oncol. 2004;34:594–601.
34. Kim SH, Kwon HC, Oh SY, Lee DM, Lee S, Lee JH, et al. Prognostic value of ercc1, thymidylate synthase, and glutathione s-transferase pi for 5-fu/oxaliplatin chemotherapy in advanced colorectal cancer. Am J Clin Oncol. 2009;32:38–43.
35. Subbarayan PR, Sarkar M, Nelson G, Benitez E, Singhal S, Ardalan B. Chronic exposure of colorectal cancer cells in culture to fluoropyrimidine analogs induces thymidylate synthase and suppresses p53. A molecular explanation for the mechanism of 5-fu resistance. Anticancer Res. 2010;30:1149–56.
36. Tsujimoto H, Tsukioka S, Ono S, Sakamoto E, Sakamoto K, Tsuta K, et al. Effect of leucovorin on the antitumor efficacy of the 5-fu prodrug, tegafur-uracil, in human colorectal cancer xenografts with various expression levels of thymidylate synthase. Oncol Lett. 2010;1:973–80.
37. Tanaka-Nozaki M, Tajiri T, Tanaka N, Furukawa K, Takasaki H, Yoshimura K, et al. Intratumoral induction of thymidylate synthase mrna by 5-fu in colorectal cancer patients: association with survival. Oncol Rep. 2003;10:1425–9.
38. Raymond E, Louvet C, Tournigand C, Coudray AM, Faivre S, De Gramont A, et al. Pemetrexed disodium combined with oxaliplatin, sn38, or 5-fluorouracil, based on the quantitation of drug interactions in human ht29 colon cancer cells. Int J Oncol. 2002;21:361–7.
39. Bischof M, Huber P, Stoffregen C, Wannenmacher M, Weber KJ. Radiosensitization by pemetrexed of human colon carcinoma cells in different cell cycle phases. Int J Radiat Oncol Biol Phys. 2003;57:289–92.
40. Avallone A, Di Gennaro E, Silvestro L, Iaffaioli VR, Budillon A. Targeting thymidylate synthase in colorectal cancer: critical re-evaluation and emerging therapeutic role of raltitrexed. Expert Opin Drug Saf. 2014;13:113–29.
41. Lee KH, Hur HS, Im SA, Lee J, Kim HP, Yoon YK, et al. Rad001 shows activity against gastric cancer cells and overcomes 5-fu resistance by downregulating thymidylate synthase. Cancer Lett. 2010;299:22–8.
42. Danielsen SA, Eide PW, Nesbakken A, Guren T, Leithe E, Lothe RA. Portrait of the pi3k/akt pathway in colorectal cancer. Biochim Biophys Acta. 1855;2015:104–21.
43. Franke TF. Pi3k/akt: getting it right matters. Oncogene. 2008;27:6473–88.
44. Manning BD, Cantley LC. Akt/pkb signaling: navigating downstream. Cell. 2007;129:1261–74.
45. Fulda S. The pi3k/akt/mtor pathway as therapeutic target in neuroblastoma. Curr Cancer Drug Targets. 2009;9:729–37.
46. Chiarini F, Del Sole M, Mongiorgi S, Gaboardi GC, Cappellini A, Mantovani I, et al. The novel akt inhibitor, perifosine, induces caspase-dependent apoptosis and downregulates p-glycoprotein expression in multidrug-resistant human t-acute leukemia cells by a jnk-dependent mechanism. Leukemia. 2008;22:1106–16.
47. Fei HR, Chen G, Wang JM, Wang FZ. Perifosine induces cell cycle arrest and apoptosis in human hepatocellular carcinoma cell lines by blockade of akt phosphorylation. Cytotechnology. 2010;62:449–60.
48. Chen GQ, Tang CF, Shi XK, Lin CY, Fatima S, Pan XH, Yang DJ, Zhang G, Lu AP, Lin SH, Bian ZX: Halofuginone inhibits colorectal cancer growth through suppression of akt/mtorc1 signaling and glucose metabolism. Oncotarget 2015
49. Liu G, Song Y, Cui L, Wen Z, Lu X. Inositol hexaphosphate suppresses growth and induces apoptosis in ht-29 colorectal cancer cells in culture: Pi3k/akt pathway as a potential target. Int J Clin Exp Pathol. 2015;8:1402–10.
50. Prabhu VV, Allen JE, Dicker DT, El-Deiry WS. Small-molecule onc201/tic10 targets chemotherapy-resistant colorectal cancer stem-like cells in an akt/foxo3a/trail-dependent manner. Cancer Res. 2015;75:1423–32.
51. Qin J, Teng J, Zhu Z, Chen J, Huang WJ: Genistein induces activation of the mitochondrial apoptosis pathway by inhibiting phosphorylation of akt in colorectal cancer cells. Pharmaceutical biology 2015:1-6.
52. Tang Y, Liu P, Tian Y, Xu Y, Ren F, Cui X, et al. Overexpression of ribonuclease inhibitor defines good prognosis and suppresses proliferation and metastasis in human colorectal cancer cells via pi3k/akt pathway. Clin Transl Oncol. 2015;17:306–13.
53. Wang F, Ruan XJ, Zhang HY. Bde-99 (2,2′,4,4′,5-pentabromodiphenyl ether) triggers epithelial-mesenchymal transition in colorectal cancer cells via pi3k/akt/snail signaling pathway. Tumori. 2015;101:238–45.
54. Nagaraju GP, Alese OB, Landry J, Diaz R, El-Rayes BF. Hsp90 inhibition downregulates thymidylate synthase and sensitizes colorectal cancer cell lines to the effect of 5fu-based chemotherapy. Oncotarget. 2014;5:9980–91.
55. Kang FB, Wang L, Jia HC, Li D, Li HJ, Zhang YG, et al. B7-h3 promotes aggression and invasion of hepatocellular carcinoma by targeting epithelial-to-mesenchymal transition via jak2/stat3/slug signaling pathway. Cancer Cell Int. 2015;15:45.